Synthon Successfully Concluded Phase I Clinical Trial for Trastuzumab
Synthon’s first truly biosimilar product now embarking on phase III study
All in vitro and in vivo studies conducted so far showed biosimilar behavior of Synthon’s trastuzumab in comparison with the reference product, Herceptin®. The outcome of the phase I clinical trial confirmed these results, showing bio-equivalence of Synthon’s trastuzumab to Herceptin®.
“Trastuzumab is one of the most advanced biopharmaceutical products of Synthon’s pipeline, and is now ready to go into a confirmatory phase III clinical trial in breast cancer patients,” says Rudy Mareel, CEO Synthon. “Biosimilars are to Synthon a serious stepping stone towards the development of biosuperior and truly innovative biological products. We are very excited about our growing portfolio of new biological antiproliferative agents that is well positioned next to our biosimilars.”
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.